271 related articles for article (PubMed ID: 17259658)
1. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection.
Molleví DG; Serrano T; Ginestà MM; Valls J; Torras J; Navarro M; Ramos E; Germà JR; Jaurrieta E; Moreno V; Figueras J; Capellà G; Villanueva A
Carcinogenesis; 2007 Jun; 28(6):1241-6. PubMed ID: 17259658
[TBL] [Abstract][Full Text] [Related]
2. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
3. P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection.
Yang Y; Forslund A; Remotti H; Lönnroth C; Andersson M; Brevinge H; Svanberg E; Lindnér P; Hafström L; Naredi P; Lundholm K
Cancer; 2001 Feb; 91(4):727-36. PubMed ID: 11241240
[TBL] [Abstract][Full Text] [Related]
4. Characterization of p53 mutations in colorectal liver metastases and correlation with clinical parameters.
Tullo A; D'Erchia AM; Honda K; Mitry RR; Kelly MD; Habib NA; Saccone C; Sbisà E
Clin Cancer Res; 1999 Nov; 5(11):3523-8. PubMed ID: 10589767
[TBL] [Abstract][Full Text] [Related]
5. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
[TBL] [Abstract][Full Text] [Related]
6. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
Chang SC; Lin JK; Lin TC; Liang WY
Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
Ständer M; Peraud A; Leroch B; Kreth FW
Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.
Peraud A; Kreth FW; Wiestler OD; Kleihues P; Reulen HJ
Clin Cancer Res; 2002 May; 8(5):1117-24. PubMed ID: 12006527
[TBL] [Abstract][Full Text] [Related]
9. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
10. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
[TBL] [Abstract][Full Text] [Related]
11. p53 alterations are associated with improved prognosis in distal colonic carcinomas.
Soong R; Grieu F; Robbins P; Dix B; Chen D; Parsons R; House A; Iacopetta B
Clin Cancer Res; 1997 Aug; 3(8):1405-11. PubMed ID: 9815825
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma.
Russo A; Corsale S; Agnese V; Macaluso M; Cascio S; Bruno L; Surmacz E; Dardanoni G; Valerio MR; Vieni S; Restivo S; Fulfaro F; Tomasino RM; Gebbia N; Bazan V
J Cell Physiol; 2006 Jan; 206(1):181-8. PubMed ID: 15965904
[TBL] [Abstract][Full Text] [Related]
13. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases.
Petrowsky H; Sturm I; Graubitz O; Kooby DA; Staib-Sebler E; Gog C; Köhne CH; Hillebrand T; Daniel PT; Fong Y; Lorenz M
Eur J Surg Oncol; 2001 Feb; 27(1):80-7. PubMed ID: 11237496
[TBL] [Abstract][Full Text] [Related]
14. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
Dotor E; Cuatrecases M; Martínez-Iniesta M; Navarro M; Vilardell F; Guinó E; Pareja L; Figueras A; Molleví DG; Serrano T; de Oca J; Peinado MA; Moreno V; Germà JR; Capellá G; Villanueva A
J Clin Oncol; 2006 Apr; 24(10):1603-11. PubMed ID: 16575011
[TBL] [Abstract][Full Text] [Related]
15. p53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma.
Kahlenberg MS; Stoler DL; Rodriguez-Bigas MA; Weber TK; Driscoll DL; Anderson GR; Petrelli NJ
Cancer; 2000 Apr; 88(8):1814-9. PubMed ID: 10760757
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance in molecular detection of p53 mutation in serum of patients with colorectal carcinoma.
Ito T; Kaneko K; Makino R; Konishi K; Kurahashi T; Ito H; Katagiri A; Kushima M; Kusano M; Mitamura K; Imawari M
Oncol Rep; 2003; 10(6):1937-42. PubMed ID: 14534722
[TBL] [Abstract][Full Text] [Related]
17. [Association of TP53 gene polymorphisms with genetic susceptibility to liver metastases of colorectal cancer].
Wang AZ; Zhu ZZ; Cong WM
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Apr; 25(2):168-71. PubMed ID: 18393238
[TBL] [Abstract][Full Text] [Related]
18. High incidence of protein-truncating mutations of the p53 gene in liver metastases of colorectal carcinomas.
Miyaki M; Iijima T; Yasuno M; Kita Y; Hishima T; Kuroki T; Mori T
Oncogene; 2002 Sep; 21(43):6689-93. PubMed ID: 12242668
[TBL] [Abstract][Full Text] [Related]
19. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
[TBL] [Abstract][Full Text] [Related]
20. p53, DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer.
Saw RP; Koorey D; Painter D; Gallagher PJ; Solomon MJ
Br J Surg; 2002 Nov; 89(11):1409-15. PubMed ID: 12390383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
